Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
View/ Open
Date
2017-06Author
Stewart, GD
Aitchison, M
Bex, A
Larkin, J
Lawless, C
Méjean, A
Nathan, P
Oades, G
Patard, J-J
Paul, J
Ravaud, A
Escudier, B
Renal Cross Channel Group
Type
Journal Article
Metadata
Show full item recordAbstract
Despite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed early (SURTIME) or are recruiting very slowly (CARMENA) after 7 yr. Challenges in RCT delivery in uro-oncologic surgery are many. Multiple steps are needed to ensure strong recruitment to trials addressing important urologic cancer questions. Feasibility/pilot studies are key stepping stones towards successful delivery of surgical RCTs.
Collections
Subject
Renal Cross Channel Group
Humans
Carcinoma, Renal Cell
Kidney Neoplasms
Antineoplastic Agents
Protein Kinase Inhibitors
Treatment Outcome
Chemotherapy, Adjuvant
Nephrectomy
Evidence-Based Medicine
Randomized Controlled Trials as Topic
Molecular Targeted Therapy
Cytoreduction Surgical Procedures
Research team
Melanoma and Kidney Cancer
Language
eng
Date accepted
2016-10-14
License start date
2017-06
Citation
European urology, 2017, 71 (6), pp. 845 - 847